<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983589</url>
  </required_header>
  <id_info>
    <org_study_id>M21-195</org_study_id>
    <nct_id>NCT04983589</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily</brief_title>
  <acronym>ORION</acronym>
  <official_title>A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of BID Dosing of AGN-190584 in Subjects With Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently available treatments for presbyopia (old eye) include nonsurgical options&#xD;
      (spectacles or contact lenses) and surgical options, however, each has its own risks and&#xD;
      limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating&#xD;
      presbyopia compared to vehicle (placebo).&#xD;
&#xD;
      AGN-190584 is an investigational drug being developed for the treatment of presbyopia.&#xD;
      Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a&#xD;
      different treatment. There is a 1 in 2 chance that participants will be assigned to vehicle.&#xD;
      Around 200 participants age 40-55 years with a diagnosis of presbyopia will be enrolled in&#xD;
      the study in approximately 20 sites in the United States.&#xD;
&#xD;
      Participants will receive AGN-190584 or vehicle in each eye twice daily for 14 days.&#xD;
&#xD;
      There may be additional procedures for participants in this trial compared to their standard&#xD;
      of care. Participants will attend regular visits during the study at a doctor's office. The&#xD;
      effect of the treatment will be checked by medical assessments, vision/eye tests, checking&#xD;
      for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Gaining 3 Lines or More in Mesopic, High-Contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) with No More than 5-Letter Loss in Mesopic Corrected Distance Visual Acuity (CDVA) with the Same Refractive Correction</measure>
    <time_frame>Day 14</time_frame>
    <description>Both near vision and distance vision are measured to evaluate the effect of AGN-190584.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Gaining 3 Lines or More in Photopic, High-Contrast, Binocular DCNVA with No More than a 5-Letter Loss in Photopic CDVA with the Same Refractive Correction</measure>
    <time_frame>Day 14</time_frame>
    <description>Both near vision and distance vision are measured to evaluate the effect of AGN-190584.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Gaining 2 Lines or More in Mesopic, High-Contrast, Binocular DCNVA with No More than a 5-Letter Loss in Mesopic CDVA with the Same Refractive Correction</measure>
    <time_frame>Day 14</time_frame>
    <description>Both near vision and distance vision are measured to evaluate the effect of AGN-190584.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 20/40 or Better in Mesopic, High-Contrast, Binocular DCNVA with No More than a 5-Letter Loss in Mesopic CDVA with the Same Refractive Correction</measure>
    <time_frame>Day 14</time_frame>
    <description>Both near vision and distance vision are measured to evaluate the effect of AGN-190584.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>AGN-190584</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop bilaterally twice daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop bilaterally twice daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-190584</intervention_name>
    <description>Ocular drops</description>
    <arm_group_label>AGN-190584</arm_group_label>
    <other_name>Pilocarpine HCl 1.25%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Ocular drops</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Objective and subjective evidence of presbyopia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Corneal abnormalities (including keratoconus, corneal scar, Fuchs' endothelial&#xD;
             dystrophy, guttata, or edema) in either eye that are likely to interfere with visual&#xD;
             acuity.&#xD;
&#xD;
          -  Narrow iridocorneal angles (Shaffer grade &lt;=2 or lower on gonioscopy examination),&#xD;
             history of angle-closure glaucoma, or previous iridotomy.&#xD;
&#xD;
          -  Diagnosis of any type of glaucoma or ocular hypertension.&#xD;
&#xD;
          -  History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery,&#xD;
             radial keratotomy, or any intraocular surgery.&#xD;
&#xD;
          -  Use of temporary or permanent punctal plugs or history of punctal cautery in one or&#xD;
             both eyes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Empire Eye and Laser /ID# 231433</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309-0637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Global Research Management /ID# 231300</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204-2500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>United Medical Research Institute /ID# 233982</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group, Inc. /ID# 231270</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345-1200</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Eye Research Foundation /ID# 231274</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663-3637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Martel Eye Medical Group /ID# 231332</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670-2968</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research - Crystal River /ID# 231298</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bruce Segal, MD /ID# 231413</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484-6540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clayton Eye Clinical Research, LLC /ID# 231243</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260-4180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jacksoneye, SC /ID# 231374</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <zip>60046-8563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Price Vision Group /ID# 231261</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260-5381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kannarr Eye Care /ID# 231363</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762-2620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute- Edgewood /ID# 231356</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017-3415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Eye Care Institute /ID# 231275</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206-1738</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rochester Ophthalmological Group PC /ID# 231371</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618-2616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern College of Optometry /ID# 231325</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104-2211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Total Eye Care, PA /ID# 231245</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119-5745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advancing Vision Research /ID# 231244</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hill Country Eye Center /ID# 231293</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613-7651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cataract &amp; Glaucoma Center /ID# 231292</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902-1444</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eye associates /ID# 231262</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hoopes, Durrie, Rivera Research /ID# 231273</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020-7133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Country Hills Eye Center /ID# 231414</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403-2200</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Presbyopia</keyword>
  <keyword>AGN-190584</keyword>
  <keyword>Pilocarpine HCl 1.25%</keyword>
  <keyword>Old Eye</keyword>
  <keyword>Aged Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

